Worldwide Study Of New Drug For Patients With Pancreatic Cancer To Be Presented At ASCO 2013
Physicians at the Virginia G. Piper Cancer Center at Scottsdale Healthcare were first to design a clinical trial to determine the safety, tolerability and effectiveness of nab-paclitaxel (Abraxane) in combination with the standard drug gemcitabine in patients with advanced pancreatic cancer. Results of that multicenter study chaired by Dr. Daniel Von Hoff were encouraging enough that it led to one of the largest international studies ever done in pancreatic cancer, with 861 patients.
Full results are expected to be presented at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium, Jan. 24-26 in San Francisco.
"This is a great example of rapid bench to bedside development of new treatments for cancer. We're ecstatic that we will have a new treatment for patients with late stage pancreatic cancer," said Dr. Von Hoff, international lead investigator and Chief Scientific Officer for the Virginia G. Cancer Center Clinical Trials at Scottsdale Healthcare and TGen's Physician-In-Chief.
The pancreas is a gland behind the stomach that secretes enzymes into the upper part of the small intestine to help digestion. It also produces hormones, including insulin, which helps regulate the metabolism of sugars. Advanced pancreatic cancer is fourth most common cause of cancer death in the United States and throughout the world. It is a difficult to diagnose and treat cancer with the lowest survival rates among all cancer types.
Nab-paclitaxel (Abraxane) is an albumin-bound formulation of paclitaxel, produced by Celgene Corp. Dr. Von Hoff said that results of the MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study will lead Celgene to submit for FDA approval.
"Pancreatic cancer incidence is increasing worldwide with almost 220,000 cases per year, and we are optimistic that this will have worldwide impact for treating advanced pancreatic cancer," added Dr. Ramesh Ramanathan, Medical Director of Virginia G. Cancer Center Clinical Trials at Scottsdale Healthcare and principal investigator for the United States.
Dr. Von Hoff credited the support of Scottsdale Healthcare Foundation, Stand Up to Cancer and the Seena Magowitz Foundation for advancing the study at the Virginia G. Piper Cancer Center at Scottsdale Healthcare. He noted that TGen and International Genomics Consortium scientists in collaboration with scientists from Abraxis Bioscience found that in pancreatic cancer, an albumin-binding protein called SPARC was present at high levels in cells within the pancreatic tumor microenvironment. They hypothesized that the albumin formulation of nab-paclitaxel may be taken up by tumor and surrounding cells with high SPARC expression.
Individuals seeking information about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339; toll free at 1-877-273-3713 or via email at email@example.com.
The Translational Genomics Research Institute
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
The Translational Genomics Research Institute. "Worldwide Study Of New Drug For Patients With Pancreatic Cancer To Be Presented At ASCO 2013." Medical News Today. MediLexicon, Intl., 22 Nov. 2012. Web.
26 Aug. 2016. <http://www.medicalnewstoday.com/releases/253025.php>
The Translational Genomics Research Institute. (2012, November 22). "Worldwide Study Of New Drug For Patients With Pancreatic Cancer To Be Presented At ASCO 2013." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.